Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 (Volagidemab) Pilot Study in T1D
NCT03919617Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volagidemab in type 1 diabetes mellitus (T1D), sponsored by University of California, San Diego. Primary endpoints: Change in Beta-hydroxybutyrate Level at 4 weeks, Rate of De Novo Lipogenesis at 4 weeks and 2 more. Started Jul 2019; status: completed.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03919617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919617.